Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT) -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (467)	3/7/2000 3:28:00 PM
From: Dennis	Read Replies (1) \| Respond to of 687

Anything goes in this crazy market....time to hunker down till the storm passes......26% of S&P at 52 week lows....1% at 52 week high....according to CNBC....think this will make Uncle Al Greenspam happy???? The rich just can't stand it when the little guys are making money......incredible. Good Luck

To: Jack Hartmann who wrote (467)	3/29/2000 3:36:00 PM
From: Mike	Read Replies (2) \| Respond to of 687

Lawsuit on the S670 Stent by: cashcow75 3/29/00 3:25 pm Msg: 5653 of 5653 NATICK, Mass., March 29 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX - news) announced today that it has filed a patent infringement lawsuit against Medtronic AVE, Inc. to enforce the Bonzel Rapid Exchange patent rights it acquired with Schneider Worldwide in September 1998. The suit, filed in United States District Court for the Northern District of California, alleges that the S670 Rapid Exchange Coronary Stent System manufactured and sold by Medtronic AVE, Inc. infringes the Bonzel patent. Boston Scientific is seeking damages as well as preliminary and permanent injunctive relief. Rapid exchange technology, also referred to as Monorail(TM) catheter technology, allows physicians to more easily exchange balloon catheters during a procedure. The ability to exchange devices rapidly is important because it helps reduce both procedure time and costs. The use of rapid exchange technology also improves patient comfort and safety. Jim Tobin, Boston Scientific President and Chief Executive Officer, commented on the lawsuit, ``We made a major investment in acquiring the Schneider business and its intellectual property rights. The Bonzel patent protects the use of rapid exchange technology which offers procedural advantages to interventional cardiologists. It is preferred by many physicians. Boston Scientific will vigorously enforce and protect its intellectual property.'